Benzinga·2h ago·NaLiminatus Pharma to Merge with InnocsAI in $320M Oncology Cell Therapy DealLiminatus Pharma to acquire InnocsAI in $320M stock-based merger, gaining CAR-T oncology candidates IBC101 and INC101. LIMNLIMNWmergersolid tumors
Benzinga··Na